Maybe you could DD a bit further and see how those companies are doing today. Not sure yet if I will roll the dice here again.
The only hope is that the guilty will spend a significant time in jail. I got out at .01. If it goes to .0001, I may jump in and buy 10,000,000 shares. It's tough letting go.
Louis Porter / Chairman, Bayport Corporation
Mr. Louis Porter of Tulsa, Oklahoma is CEO and Board Chairman of Bayport Corp. He received a B.S in Petroleum and Natural Gas Engineering from Texas A&I in Kingsville, Texas 1970, now affiliated with Texas A&M. He was a member of the Sigma Tau and Alpha Chi honor societies – Sigma Tau Honor Engineer Alpha Chi Honor Scholastic. He worked five years with Arco as a Petroleum Engineer, Drilling, Gasoline Plant, Reservoir Engineering and Sales of LPG’s. Then Mr. Porter spent 5 years with Thermogas as its Transportation Director, as well as Operations Manager for purchasing wholesale and the retail selling of propane and butane for the entire network. Thermogas was the largest LPG distributor of LPG’S in the nation at that time until merged with Mid America Pipeline.
He started NGL Supply (Natural Gas Liquids) which later became Dalco Petroleum a Public Company in the United States and was 87% owner of Dynex Petroleum a Public Company across Canada and headquartered in Calgary Alberta. He was CEO & Major Owner of 87% of stock in the Canadian operation & CEO and President with 90% stock in Dynex USA. Dynex was very strong in Canada with sales reaching approximately 1 Billion dollars Canadian in oil and gas. Dynex successfully engineered a $75 Million revolving line of credit with Bank of Montreal.
Thanks for the warning. Seems like you're having a bad dream. This stock isn't for weaklings. Maybe you should buy a CD or a savings bond. Good luck!
I clicked on your name to see what you've been up to. Seems like you're chilling all over the place. I had no trouble buying shares and by the volume that is being traded, seems like not many others are either. Chill out dude.
Therapix Biosciences Ltd.
Viropro Inc. (OTCPK:VPRO) signed a non-binding letter of intent to acquire Therapix Biosciences Ltd. (TASE:TRPX) from a group of investors on December 4, 2013. The investors are The Pontifax Fund, fund of Pontifax Ltd., IBI Mutual Funds Management Ltd., Gilbood Trading S.A, Quantum Technology Management Company IV, LLC and other shareholders.
The Pontifax Fund specilizes start-ups. The fund seeks to invest in pharmaceutical and life sciences companies with a focus on medical devices companies based in Israel. It seeks board representation in its portfolio companies. Mr. Ran Nussbaum is a Co-Founder, Managing Partner, and Partner at The Pontifax Group and Pontifax Ltd. Mr. Nussbaum served as the Chief Executive Officer of Biomedix. He was a Partner and General Manager of Israel's largest business intelligence company. His real life experience in the life sciences arena coupled with a 10-year experience in the business intelligence field create a unique blend of skills, enabling him to support companies from inception to commercialization. His work revolves around constant and active involvement in companies, providing them with strategic and business development oversight. He serves as the Chairman of OCON Medical Ltd. He served as the Chairman of NasVax Ltd. He serves as Vice Chairman of Biomedix (BMDX). He serves as Co-Director of The Pontifax Fund. He serves as a Director of TheraCoat Ltd., Kite Pharma, Inc., Meytav Technological Incubato, cCAM Biotherapeutics Ltd, Collplant, Protab, AIT, Fusimab Ltd ,and Omer Therapeutics Ltd.
IBI Mutual Fund Management Ltd., established in 1978, is one of the oldest and top fund firms in the mutual fund industry in Israel.
The company manages 42 mutual funds with a net asset value of approximately NIS 13 billion.*
Our mutual funds provide a highly stable and superior quality platform for capital management in all investment areas in Israel and in key investment areas overseas.
IBI's mutual funds are unique in that they reflect not only our determination to achieve superior returns but also a consistency in investment style and policy over the long term.
Our investment philosophy is, accordingly, based, first and foremost, on quality and integrity. We firmly believe that, one cannot create the quality content needed to deliver added value in each fund without in-depth knowledge, hands-on experience and the right technical parameters.
This defining infrastructure is central to the multi-tiered process that constitutes a key component in our fund management. This process is broken down as follows:
Tier one – Intelligent use of various instruments in the fixed income market aimed at achieving a superior return to risk-free interest rates.
Tier two – Leveraging financial market anomalies at both the micro- and the macro-economic levels.
Tier three – Reliance on up-to-the-minute research and in-depth knowledge to identify the equities and bonds of investment-grade companies.
We stress that along with our "Buy and Hold" style investments in growth companies and value investments, there are also instances where we make short-term investments in accordance with milestones in company development or market conditions.
Our investment philosophy combines a dynamic approach to markets with a long-term economic perspective. Markets have been exceptionally volatile post the “once in 80 years crisis,” and this volatility should not, in our opinion, be a deterrent – quite the contrary. While volatility can cause a great many difficulties, it is also the source of innumerable opportunities to locate economic value in the equity and bond markets on an absolute rather than a proportionate basis. It is precisely these opportunities that we aim for, and we make intelligent use of them in our day-to-day management in each of IBI's mutual funds .
Gilbood Trading S.A: No information
Quantum Technology Management Company IV: No information
I don't consider myself a 'moron' but if anything illegal and I'll add, unethical, has or is happening behind the scenes, I hope the guilty party, whoever that is, finds their #$%$ in jail, the same place I would end up for similar activities. The lack of transparency doesn't bode well for CT. She needs to say something to us shareholders, NOW.
Maybe so, Maybe not. We’ll see.
There is a Chinese Proverb that goes something like this…
A farmer and his son had a beloved stallion who helped the family earn a living. One day, the horse ran away and their neighbors exclaimed, “Your horse ran away, what terrible luck!” The farmer replied, “Maybe so, maybe not. We’ll see.”
A few days later, the horse returned home, leading a few wild mares back to the farm as well. The neighbors shouted out, “Your horse has returned, and brought several horses home with him. What great luck!” The farmer replied, “Maybe so, maybe not. We’ll see.”
Later that week, the farmer’s son was trying to break one of the mares and she threw him to the ground, breaking his leg. The villagers cried, “Your son broke his leg, what terrible luck!” The farmer replied, “Maybe so, maybe not. We’ll see.”
A few weeks later, soldiers from the national army marched through town, recruiting all the able-bodied boys for the army. They did not take the farmer’s son, still recovering from his injury. Friends shouted, “Your boy is spared, what tremendous luck!” To which the farmer replied, “Maybe so, maybe not. We’ll see.”
The moral of this story, is, of course, that no event, in and of itself, can truly be judged as good or bad, lucky or unlucky, fortunate or unfortunate, but that only time will tell the whole story.
So with Viropro, a good investment? Maybe so, maybe not. We'll see.
I'm here for the long term.
HAPPY NEW YEAR!
Acebright will invest $1 million in NasVax
Globes Friday, 06 September 2013
Chinese pharmaceutical company Acebright Holdings Ltd. will invest $1 million in NasVax Ltd., an Israel based developer of immunotherapies.
The two companies also signed a nonbinding memorandum of understanding granting Acebright an exclusive license to develop and conduct clinical trials of NasVax's Anti-CD3 technology for the treatment of non-alcoholic steatohepatitis (NASH), or fatty liver disease, only, and to commercialize it in the Far East, including China, Hong Kong, Korea, Thailand, the Philippines, and India, but excluding Japan.
Acebright's investment will include $450,000 in NasVax itself for an allotment of 10.5 million shares, 7.5% of the company, and $550,000 in two subsidies to which it will transfer two technologies: the anti-CD3 technology, and the BBS technology for the treatment of Alzheimer's.
NasVax will also allot to Acebright 26.3 million warrants, exercisable for shares over 12 months, for an additional investment of $1.12 million.
NasVax CEO Ari Aminetzah said, "This is NasVax's first important step toward a fertile long-term collaboration with Acebright. The collaboration is based on the mutual ambition and strong commitment to accelerate the further development of our oral treatment for fatty liver disease."
I'm serious. Give me a reason to buy and I'll do it. When is a new CEO going to be appointed at Alpha? Maybe it will be the new scientist that interviewed CT. Until a new CEO is brought online, things will continue to look a bit shaky.
Viropro International Inc., (OTCMarkets:VPRO) Takes Its Directors To Court on Fraud Allegations
By Mark Freeman
Viropro International Inc.
Boston, MA, 11/06/2013 (nysepost) – Viropro International Inc., (OTCMarkets:VPRO) is a micro market capped biotech research firm which operates through its Canada subsidiary Viropro Pharma Inc. It makes money by inventing and discovering various drug manufacturing technologies and in turn transferring the same to companies which take it to the market. In lieu of the technology transfer the firm will get paid royalties or outright sale consideration. It also is into developing new drugs on a turnkey basis for other biotech and pharma firms. The firm has its market spread across the emerging markets like Africa, South America and India.
As of close of business on November 4, the stock was trading at $0.02 per share which has been oscillating between $0.01 and $0.02 over the past few months. The stock seems to be shell shocked into a stupor by the news that company directors who had been entrusted with the duty of safeguarding the company and its share holders interest had been found with their hands in the proverbial cookie jar. The company had moved swiftly to relieve the suspected directors of their duties and took them to court.
The firm had announced on October 27 that it was taking its former directors Kenneth Sorensen and Michelle Peake to the court of Second Judicial District Court of the State of Nevada. The drug firm has alluded that the directors were guilty of “breach of fiduciary duties, declaratory relief, injunction, and civil conspiracy” to defraud the company and in turn its share holders. On October 28 the firm further added to the charges by citing fraud and intentional misconduct on part of the same directors in their grand scheme to defraud the share holders of the firm. Viropro claims that it took this legal action to safe guard and help protect the interes